Dear Reader, If you're already seeing at least 100% gains on at least half of every idea you might put money in... Congrats, you're among the best in the world. For everyone else, I highly recommend you see this today before it disappears. It starts with a moving personal story that you absolutely need to see... And leads to a multi-decade investing opportunity that is not going anywhere, no matter what the market does next... Covered by an analyst whose work is so elite and – normally – so expensive, that you may not even be aware of him. Until tomorrow, you can try it for more than 60% OFF – less than even the best discounts we typically offer for any similar work – and claim a $2,500 valued bonus, by itself worth MORE than the entire cost to get started. His name is Dave Lashmet. In the early days of our firm, Dave recommended an early-stage biotech firm called Regeneron before its very first drug approval – and before 5,800%-plus gains over the long term: He saw the potential in the genomics pioneer Illumina (ILMN) years before almost anyone else when the stock was trading around just $6 a share. Shares soared nearly 17,000% in the following decades: And he recommended Seagen (SGEN) in 2004 when it traded around $10. Just last year, Pfizer bought out the company (in a $43 billion deal ) for $229 a share... nearly 2,200% higher than where he first highlighted it: Well today, he's sharing the details of five opportunities that could be similar. And – nobody knows this yet – but he's days away from releasing a brand-new recommendation that he believes has 800% upside potential. It's part of the same once-a-generation situation he's detailing today. And you can be among the very first to take action on it. But only by accepting this one-time-only invitation before tomorrow, or the price will more than double. Now, Dave's done all this in an elite research letter that's designed to show readers massive gains using a "venture capital"-like investing approach... But without the hassle (and greater risk) of investing in the private market, which is off-limits to most people and often involves massive fees (not to mention locking your money up for years). That means building a portfolio of early-stage companies with breakthrough products – the kind that could transform entire industries. It's an ambitious approach, but one where even one or two winners could make you EXTREMELY wealthy... And where allocating even a small percentage of your investing money could make all the difference in your future results. One reason why I think every reader who can should at least consider this one-time-only invitation while it's still available – unfortunately, it expires forever TOMORROW. Keep in mind that when we first introduced this research, Dave's very first three recommendations soared 107%... 134%... and 150%. And get this... In May of 2016, he first recommended what's probably the No. 1 hottest stock in the world today, chipmaker Nvidia (NVDA). Readers had the chance to lock in a 1,466% gain – one of the biggest in our company's history. And the following year, he recommended a then roughly half-billion dollar drugmaker for its promising heart drug. He recommended selling half for a 100% gain... and the remaining position is up more than 800% so far: In 2019, he recommended a 691% winner in February ... And then a 1,139% winner four months later. Of course, there are dozens of double- and triple-digit gains I'm not mentioning here. Just take a look at these published updates from Dave's work... and see if you notice a theme: Not to mention these: Just so you know I'm not "cherry picking" – this has been the outcome in 25 out of 50 closed positions so far. Meaning that even in the inherently speculative realm of emerging technology and biotech, half of Dave's recommended positions have at least doubled. And he's recommended that readers lock in the double... leaving a remaining position that could go on for high triple-digit and even quadruple-digit gains without risking the original principal. Now, he's zeroed in on a story so big that it's changing the entire landscape of medicine going forward – you can see what I mean here. But simply understanding this won't do anything for you. You have to have the foresight to act – and act today. It's a lot like the Internet revolution... It didn't end with the first big web browser or email client. (Remember when Netscape was No. 1?) Or even when Google established a stranglehold on web search. Those steps were just the beginning... They created a whole new ecosystem that changed the world. Imagine you'd subscribed back in 1999 to a research letter diving into everything the digital revolution promised to do and create... Written by someone with even a fraction of Dave's expertise. It's hard to imagine you couldn't have become a multi-millionaire. That's exactly the situation today, right now – it's right in front of you for the taking. Yes, investing in biotechnology is speculative. Seeing high triple-digit winners – and even more – will almost certainly mean seeing some losers along the way, too. But this is the kind of investing where even a handful of winners could "pay for" any losers many times over... Change everything for your wealth... And likely accelerate your retirement. So here is what I want you to know before you make a decision... Dave operates by a crystal-clear rule of thumb: If the position doesn't offer at least 10 times more upside than risk – based on everything his incredibly in-depth research shows about the science and market landscape – he doesn't recommend it. End of story. I know for certain that that's the kind of tool you need in your arsenal today... And that it's extremely likely to outperform almost any other investing approach today. (Like chasing the overpriced and overhyped "Magnificent Seven" higher and higher.) Unfortunately, you only have until tomorrow to make a "yes or no" decision. Discount offers for this research are extremely rare... And the one I've authorized until tomorrow only is unprecedented in our company history. I did it to honor a colleague who shared an incredibly brave story. So please, don't delay... Click here for the full details while it's still available. Regards, Brett Aitken
Publisher, Stansberry Research P.S. Please, don't just take my word about Dave's research. We routinely hear from Stansberry Venture Technology subscribers... Like Ron S., who said: "Dave Lashmet is the BEST editor that Stansberry has. The latest winner for me was buying [your recommendation] at $64.5 and selling half at $239 . The other half I sold at $302. Crazy good. I love Dave's analytical style of writing. I wish Stansberry had 10 Dave's!! " David B. said: "'We've been the beneficiary of your advice on [your recommendation]. Recently cashed out with about 500% gain... We're a retired couple, on a fixed income, so getting the growth in the IRA is very helpful. " Christopher D. told us: "Literally five days later my investment doubled. You recommended selling immediately, which I did to lock in the gains. It doesn't seem like much, but that immediate $10,000+ profit nearly covered my cost to become a Stansberry Alliance member several years ago. " James H. gave us a compliment that goes way beyond money: "My first of your recommended positions were NVIDIA shares that I bought in August 2017 and almost quadrupled my investment... I've always been impressed with the depth of your research and the balance you strike in explaining complex subjects, medical and otherwise, in terms that a reasonably informed investor who is seeking long-term growth in a rapidly changing world can comprehend." Marty F. wrote: "Dave, I find your research fascinating and far more in-depth than I can find anywhere else. I've had countless recommendations that have made a profit. Best by far was [the tiny drugmaker you recommended in December]. Your suggestion turned my portfolio from $250k to $740k and is still growing." Or how about this note from David H.: "This is my second attempt to send you my experience concerning [your recommendation]. The market just opened so I am going to make this short. Anyway, by my rough calculations, I made $515,000. Thank you!" Standard Disclaimer: The investment results described in these testimonials may not be typical; investing in securities carries a high degree of risk; you may lose some or all of the investment. Now it's your turn to position yourself for the same kind of results... But the best offer we will ever make expires forever at midnight tomorrow. | 